期刊文献+

ANCA阴性寡免疫复合物新月体肾炎患者的临床病理特征

Clinicopathological characteristics of antineutrophil cytoplasmic antibody negative and positive pauci-immune crescentic glomerulonephritis
下载PDF
导出
摘要 目的比较抗中性粒细胞胞浆抗体(ANCA)阴性(ANCA-)与ANCA阳性(ANCA+)寡免疫复合物新月体肾炎(PICGN)临床病理特征及预后的异同。方法对住院肾活检确诊的75例PICGN患者进行流行病学、临床表现、病理特征及预后的回顾性分析。结果①ANCA-组发病年龄小于ANCA+组[(51.7±13.7)岁vs.(44.3±14.1)岁](P<0.05);②ANCA-组肉眼血尿发生率显著高于ANCA+组(56.7%vs.31.1%)(P<0.05),ANCA-组尿蛋白定量(3.7g/dvs.2.4g/d)和达到肾病范围蛋白尿患者比例(40.0%vs.15.6%)均显著高于ANCA+组(P<0.05),ANCA-组血红蛋白水平较高(9.2g/dlvs.7.8g/dl)(P<0.01);③病理检查:ANCA-组新月体形成比例显著低于ANCA+组(63.5%vs.77.8%)(P<0.01);④ANCA-组中位随访时间49个月(7~144个月),3例失访,无死亡病例。ANCA+组中位随访时间40月(6~120个月),3例失访,12例死亡。Kaplan-Meier图预测ANCA-组5年存活率显著高于ANCA+组(100.0%vs.58.0%)(P<0.01)。结论与ANCA+的PICGN相比,ANCA-患者尿检异常较重,然而肾活检新月体比例较低,慢性化病变较轻,肾外器官受累也较少,预后相对较好。 Objective To compare the clinicopathological characteristics and outcomes of the patients with antineutrophil cytoplasmic antibody (ANCA) positive and with ANCA negative pauciimmune crescentic glomerulonephritis(PICGN). Methods Data of seventy-five Chinese patients with clinical and renal biopsy-proved PICGN were analyzed retrospectively. Results Compared the patients with ANCA-,the cases with ANCA+ were older in age[(51.7±13.7) years old vs. (44.3 ±14.1) years old] (P〈0. 05). Clinically, compared with the patients in ANCA- PICGN group, patients with positive ANCA had a lower level of urinary protein (2. 4 g/d vs. 3.7 g/d)(P〈0.05), lower prevalence of nephrotic syndrome(15.6% vs. 40.0%)(P〈0. 05) and gross hematuria(31.1% vs. 56.7%)(P〈 0.05). Pathologically, the degree of crescent formation was markedly higher in ANCA+ than that in ANCA- PICGN patients(77.8% vs. 63. 5%)(P〈0. 01). Death rate was 26.6% in ANCA+ group while none in ANCA- group. The patients with ANCA+ and ANCA- had been received a median follow-up of 40 (range 6- 120) and 49 (range 7- 144) months, respectively. The 5-year renal survival cumulative proportion of patients with ANCA+ and ANCA- was 37.5% and 61.5% ,respectively. Conclusion The patients with ANCA+ and ANCA- PICGN have many marked differences in clinical manifestations, renal histological lesion and prognosis. It may be the different characteristics that more nephrotic syndrome and gross hematuriathe, but less extrarenal involvement, milder renal insufficiency level, less chronic lesions, and better outcomes are more common in paitents with ANCA-- PICGN. ANCA-- PICGN might represent an independent disease entity from ANCA+PICGN.
出处 《江苏医药》 CAS CSCD 北大核心 2008年第9期891-894,共4页 Jiangsu Medical Journal
关键词 系统性血管炎 抗中性粒细胞胞浆抗体 寡免疫复合物新月体肾炎 Systemic vasculltis Antineutrophil cytoplasmic antibody Pauci-immune crescentic glomerulonephritis
  • 相关文献

参考文献2

二级参考文献14

  • 1Han WK,Choi HK,Roth RM,et al.Serial ANCA titers:useful tool for prevention of relapses in ANCA-associated vasculitis.Kidney Int,2003,63:1079-1085
  • 2Tang Z,Yao XD,Hu WX,et al.The clinical and pathological characteristics of Chinese patients with pauci-immune crescent glomerulonephritis.Nephrology,2000,5:155-159
  • 3Matic G,Michelsen A,Hofmann D,et al.Three cases of C-ANCA positive vasculitis treated with immunoadsorption:possible benefit in early treatment.Ther Apher,2001,5 (1):68
  • 4Pusey CD,Rees AJ,Evans DJ,et al.Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies.Kidney Int,1991,40:757-763
  • 5Rasmussen N.Consensus therapeutic regimens for ANCA-associated systemic vasculitis.The European Community Systemic Vasculitis Study Group.Lancet,1997,349 (9057):1029-1030
  • 6Jayne DR,Chapel H,Adu D,et al.Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.QJM,2000,93:433-439
  • 7Booth A,Harper L,Hammad T,et al.Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.J Am Soc Nephrol,2004,15:717-721
  • 8Specks U,Fervenza FC,McDonald TJ,et al.Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.Arthritis Rheum,2001,44:2836-2840
  • 9Hagen EC,de Keizer RJ,Andrassy K,et al.Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin.Clin Nephrol,1995,43:351-359
  • 10Lockwood CM,Thiru S,Stewart S,et al.Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.QJM,1996,89:903-912

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部